Aleksandr L. Urakov
1,2* 
, Natalya A. Urakova
1, Ilnur I. Yagudin
1, Milena D. Svetova
1, Darya O. Suntsova
11 Izhevsk State Medical Academy, Kommunarov str., 281, Izhevsk, Russia, 426034
2 Udmurt Federal Research Center, Ural Branch of the Russian Academy of Sciences, 34 Tatiana Baramzina Street, Izhevsk, Russia, 426067
Abstract
COVID-19 causes non-specific pneumonia, which has become a new cause of hypoxia, leading to the death of many patients. Today, there are no effective drugs that provide an urgent increase in blood oxygenation. Therefore, it is urgently necessary to develop drugs to increase blood oxygenation in order to save the lives of patients with the new coronavirus infection. Since hypoxia develops in this disease due to the blockage of respiratory tract with viscous mucus and sputum, an appropriate experimental model is needed for screening and finding new drugs. However this model is yet missing. Therefore, the development of an experimental model of respiratory obstruction by sputum with traces of blood can accelerate the discovery of drugs that eliminate hypoxia and prevent the death of patients with nonspecific pneumonia complicated by respiratory obstruction. The purpose of this letter was to present a model for evaluating the biological activity of drugs, which can become a new vector for the development of effective ways to increase blood oxygenation across pulmonary and save the lives of patients with severe atypical pneumonia complicated by respiratory obstruction in COVID-19.